NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Vaccine Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Finance



Molecular medicine-focused company reports results for first half of 2005



September 14th, 2005

During the first 6 months of 2005, Mologen reports investments in an expansion of the dSLIM segment and a better capitalization.

The consolidated financial statement, compiled with IFRS, shows Mologen to have had a business volume of EUR.4 million (US$.49 million) in the first half of 2005. The volume is expected to increase significantly in the second half year, due to the revenues anticipated from cell- and gene-therapy centers. In the first half of 2004, the business volume was EUR1.1 million (US$1.35 million).

The operational cash flow was EUR-1.7 million (US.-$2.09 million) during the first half of 2005 due to increased activities in research...


Source: Vaccine Weekly (2005-09-14)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login